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ABSTRACT  15 
AmBisome® (LAmB), a liposomal formulation of amphotericin B (AmB), is a second-line 16 
treatment for the parasitic skin disease cutaneous leishmaniasis (CL). Little is known about 17 
its tissue distribution and pharmacodynamics to inform clinical use in CL. Here, we 18 
compared the skin pharmacokinetics of LAmB with Fungizone® (DAmB), the deoxycholate 19 
form of AmB, in murine models of Leishmania major CL.  Drug levels at the target site (the 20 
localized lesion) 48 hours after single intravenous (IV) dosing of the individual AmB 21 
formulations (1 mg/kg of body weight) were similar, but were 3-fold higher for LAmB than 22 
for DAmB on day 10 after multiple administrations (1 mg/kg on days 0, 2, 4, 6 and 8). After 23 
single and multiple dosing, intralesional concentrations were respectively 5- and 20-fold 24 
higher compared to those in the healthy control skin of the same infected mice. We then 25 
evaluated how drug levels in the lesion after LAmB treatment relate to therapeutic outcomes. 26 
After five administrations of the drug at 0, 6.25 or 12.5 mg/kg (IV), there was a clear 27 
correlation between dose level, intralesional AmB concentration and relative reduction in 28 
parasite load and lesion size (R
2 
values > 0.9). This study confirms the improved efficacy of 29 
the liposomal over the deoxycholate AmB formulation in experimental CL, which is related 30 
to higher intralesional drug accumulation.  31 
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 40 
INTRODUCTION 41 
Cutaneous leishmaniasis (CL) is a vector-borne neglected tropical disease caused by 42 
intracellular protozoan Leishmania parasites. Current estimates suggest 350 million people at 43 
risk, 12 million cases per year and 1-1.5 million new cases annually in more than 98 44 
countries, of which the majority occurs in Latin America and the Middle East (1). While 45 
mortality is limited for the most common form, localized CL, morbidity is serious due to 46 
ulceration, disfigurement and often permanent scarring after healing of the lesion, which are 47 
all associated with social stigmatization. More complex and potentially dangerous forms of 48 
CL are diffuse (diffuse cutaneous leishmaniasis, DCL), chronic (leishmaniasis recidivans, 49 
CCL) or destructive to the nasopharyngeal mucosa (mucocutaneous leishmaniasis, MCL). 50 
Current treatments are hampered in their clinical value by toxicity, side effects, variable 51 
efficacy, high cost or invasive administration route. First-line treatment consists of 52 
pentavalent antimonials, second-line chemotherapeutic options include paromomycin, 53 
miltefosine and amphotercin B (AmB). AmB, a macrocyclic polyene antibiotic and important 54 
antifungal agent derived from Streptomyces nodosus, is active due to complexation with 55 
ergosterol in leishmanial cell membranes, leading to the formation of pores and ultimately 56 
pathogen death (2). Due to infusion-related and acute (nephro)toxicity issues of the classic 57 
colloidal dispersion with deoxycholate (Fungizone®, DAmB), lipid formulations with an 58 
improved tolerability profile and different physicochemical properties were developed, 59 
including a phospholipid complex (Abelcet®), a dispersion with cholesteryl esters 60 
(Amphocil™), a multilamellar liposome (Fungisome®) and a unilamellar liposome 61 
(AmBisome®, LAmB) (3).  62 
No standard dose regimens have been established for LAmB in the treatment of CL, as 63 
published data are limited to small case series or individual case reports (4), but clinical 64 
success has been achieved with a course of daily 3 mg/kg for a total dose of 18-21 mg/kg. 65 
Due to the need for intravenous administration of LAmB and the related risk of systemic 66 
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adverse effects, it is typically reserved as a 2
nd
 line treatment for complex CL. This includes 67 
patients with (or at risk of) MCL, DCL or CCL, but also cases where lesions are large, 68 
numerous, potentially disfiguring, unresponsive to earlier therapeutic attempts and 69 
aesthetically or practically unfeasible to cure locally.  General limitations of LAmB include 70 
the high price as well as the requirements for cold chain, slow infusion and hospitalization 71 
(5). Despite the relative safety and efficacy of LAmB in CL, fundamental questions about its 72 
pharmacology for this disease remain unanswered. Evaluation of pharmacokinetics (PK) and 73 
pharmacodynamics (PD) in preclinical models is important to inform optimal clinical use and 74 
learn lessons for drug development. A number of studies have looked at the difference in PK 75 
and PD properties of AmB formulations in the treatment of invasive fungal pathologies (6-76 
11), but none have done so for CL. Here, we report (i) the single dose pharmacokinetics of 77 
LAmB and DAmB in both healthy and Leishmania major-infected BALB/c mice, (ii) skin 78 
distribution after multiple dosing of LAmB and DamB in murine CL and (iii) the relationship 79 
between dose, intralesional AmB concentrations and response after LAmB treatment at three 80 
dose levels.  81 
 82 
 83 
 84 
MATERIALS AND METHODS 85 
Drugs. AmBisome® (LAmB, Gilead, UK) and Fungizone (DAmB, Bristol-Myers Squib, 86 
UK) were reconstituted with sterile water as per the manufacturer’s instructions to yield stock 87 
solutions of respectively 4 mg/ml and 5 mg/ml. These were diluted in 5% aqueous dextrose to 88 
a dose of 1 mg/kg (0.02 mg per dose of 200 µl for mice of a mean weight of 20 g). For 89 
LAmB, additional doses of 6.25, 12.5 and 25 mg/kg were similarly prepared. The dilutions 90 
were prepared one day before starting the experiment and stored at 4 °C. 91 
Parasites. L. major MHOM/SA85/JISH118 parasites were cultured in Schneider’s insect 92 
medium (Sigma, UK) supplemented with 10% heat-inactivated fetal calf serum (HiFCS, 93 
Sigma, UK). These parasites were passaged each week at a 1:10 ratio of the existing culture 94 
to fresh medium in 25-ml culture flasks without a filter and incubated at 26 °C. For infection 95 
of mice, stationary-phase parasites (as confirmed by light microscopy) were centrifuged for 96 
10 min at 2100 rpm at 4 °C. The supernatant was removed, and the pellet was resuspended in 97 
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pure Schneider’s insect medium. The number of cells was estimated by microscopic counting 98 
with a Neubauer hemocytometer.  99 
In vivo L. major models of CL. Female BALB/c mice around 6 to 8 weeks old were 100 
purchased from Charles River Ltd. (Margate, UK). These mice were kept in humidity- and 101 
temperature controlled rooms (55 to 65% and 25 to 26 °C, respectively) and fed water and 102 
rodent food ad libitum. After acclimatization for 1 week, mice were randomized and 103 
subcutaneously (s.c.) injected in the shaven rump above the tail with 200 µl of a parasite 104 
suspension containing 4 x 10
7
 low-passage-number (p< 5), stationary-phase L. major 105 
promastigotes in RPMI medium. Uninfected mice received a similar, but parasite-free 106 
injection of 200 µl RPMI medium instead. Twelve days later, when a 4- to 5-mm non-107 
ulcerating nodule had formed on the rump of infected animals, mice were allocated to the 108 
different experimental groups to ensure comparable lesion sizes.    109 
Ethics statement. All animal experiments were conducted under license X20014A54 110 
according to UKHome Office regulations under the Animals (Scientific Procedures) Act 111 
1986 and EC Directive 2010/63/E. 112 
Single-dose PK study.  Uninfected and L. major-infected BALB/c mice (n = 4-5 per group) 113 
each received LAmB or DAmB at 1 mg/kg of body weight over a 1-2 minute period by an 114 
intravenous bolus (200 µl). Plasma, rump (lesion site) and back (control site) skin samples 115 
were collected at 0.5, 2, 6, 24 and 48 hours post-infusion.    116 
Multiple-dose PK and PD study. L. major-infected BALB/c mice (n = 4-5 per group) each 117 
received LAmB or DAmB at 1 mg/kg or 5% dextrose over a 1-2 minute period by an 118 
intravenous bolus (200 µl) on days 0, 2, 4, 6 and 8. Skin samples from rump (lesion site) and 119 
back (control site) were collected on day 10 (48 hours after the 5
th
 and last drug 120 
administration). This day 10 time point of sacrifice allowed direct comparison with the 121 
outcomes of the single-dose PK study (last time point: 48 hours). The alternate day dosing 122 
regimen was based on earlier data on the efficacy of LAmB in the L. major-BALB/c model 123 
of CL (12). The PD methodology can be found in the following section.      124 
Dose-concentration-response study. L. major-infected BALB/c mice (n = 4-5 per group) 125 
each received LAmB (IV) at 0, 6.25, 12.5 or 25 mg/kg on day 0, 2, 4, 6 and 8. Lesion size 126 
was measured daily in two dimensions (length and width) using digital callipers and the mean 127 
size (average of length and width) was calculated. On day 10, rump (lesion site) and back 128 
(control site) skin samples were collected and parasite load was evaluated. The methodology 129 
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to extract parasite DNA from lesions and quantify parasite load by qPCR has already been 130 
described in full detail earlier (13). 131 
Skin sample collection and preparation. After sacrificing mice (CO2), skin was harvested 132 
by surgical removal from the areas containing the localized CL lesion (at the parasite 133 
inoculation site on the rump above the tail, ‘lesion-site’) and CL-uninfected skin on the back 134 
(‘control site’). The skin tissue was cut into fine, long pieces and placed into SureLock 135 
microcentrifuge tubes (StarLab, UK) together with 1 spatula (about 100 mg) of 2 mm 136 
zirconium oxide beads (Next Advance, UK) and 1 ml phosphate buffered saline (PBS, 0.9% 137 
NaOH and pH 7.4, Sigma, UK). Samples were ground using a Bullet Blender Storm 24 138 
(NextAdvance, UK) set at speed 12 for 20 minutes to obtain a smoothly flowing homogenate 139 
and stored at -80 °C until further use. The homogenate (50 µl) was added to 250 µl of a 140 
mixture of 84:16 methanol:DMSO (HPLC grade, Fisher Chemical, UK) containing 200 141 
ng/ml tolbutamide (analytical standard, Sigma, UK) internal standard for drug extraction and 142 
protein precipitation in 96-well plates. Plates were shaken for 10 minutes at 200 rpm and 143 
centrifuged for 15 minutes at 6600 rpm at 4 °C. 150 µl supernatant was collected and stored 144 
at -80 °C until analysis. Blanks with and without internal standard as well as calibration 145 
samples with known concentrations of AmB (similarly extracted and prepared after spiking 146 
45 µl blank skin homogenate (derived from untreated BALB/c mice) with 5 µl working 147 
solutions of known AmB concentrations in 1% SDS (Sigma)) were included.  148 
Plasma sample collection and preparation. Blood samples were taken from live animals by 149 
needle pricks in the lateral tail veins and collected in Eppendorf tubes preloaded with heparin 150 
(2 µl of a 1000 units/ml stock (aq)). After centrifugation at 6500 rpm at 4 °C for 10 minutes, 151 
the supernatant plasma was collected in new tubes. Plasma samples for which concentrations 152 
of AmB above the upper limit of quantification were expected, were first diluted with drug-153 
free blank plasma derived from untreated BALB/c mice. 20 µl plasma was added to 100 µl of 154 
a 200 ng/ml tolbutamide internal standard in 84:16 methanol:DMSO. Supernatant (60 µl) was 155 
collected and further treated as described for skin samples. Again, blanks with and without 156 
internal standard and calibration standards (similarly extracted and prepared after spiking 18 157 
µl blank plasma (derived from untreated BALB/c mice) with 2 µl working solutions of 158 
known AmB concentrations in 1% SDS (Sigma)) were included.    159 
LC-MS/MS quantification of AmB. The LC-MS/MS methodology to quantify AmB levels 160 
in experimental leishmaniasis samples has been described earlier by Voak et al. (14). 161 
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Analysis was conducted at Pharmidex Pharmaceutical Sevices Ltd. (Stevenage, UK). The 162 
lower limit of quantification was 1 ng/ml.   163 
Pharmacokinetic parameters. Single dose PK parameters were estimated assuming 164 
noncompartmental analysis in WinNonlin. AUC0-48h values for skin were calculated using 165 
GraphPad Prism version 7.02.  166 
Statistical analysis. Differences among lesion sizes and parasite loads in the groups were 167 
assessed by using one-way analysis of variance (ANOVA) assuming Gaussian distribution 168 
followed by Tukey’s multiple-comparison test. Data is presented as means and standard error 169 
of the mean (SEM). A p-value < 0.05 was considered statistically significant. All analyses 170 
were performed using GraphPad Prism version 7.02. 171 
RESULTS 172 
Single dose plasma and skin PK in healthy and L. major-infected mice 173 
Plasma concentration-versus-time plots after intravenous (IV) administration of a single dose 174 
of 1 mg/kg LAmB or DAmB to uninfected and L. major-infected mice are shown in figure 1a 175 
and 1b, respectively. 1 mg/kg was used as it is the highest tolerated single dose of DAmB 176 
which does not cause signs of acute toxicity (data from pilot studies not shown). Plasma PK 177 
were similar between uninfected and infected mice for the two AmB formulations, with 178 
comparable Cmax, AUC, Cl, T1/2 and Vd (table 1). However, the plasma profiles for LAmB 179 
and DamB individually were significantly different. Compared to DAmB, LAmB achieved a 180 
higher plasma peak and systemic exposure (Cmax and AUC around 10- and 3-fold greater, 181 
respectively), but showed a shorter half life and lower clearance and volume of distribution. It 182 
should be noted that the terminal phase for LAmB was not clearly defined.    183 
AmB exposure in the rump (lesion site) and back (control site) skin, expressed as AUC0.5-48h, 184 
are shown in table 2. In uninfected animals, similar drug distribution profiles in the healthy 185 
rump (fig 1c) and back (figure 1e) tissues were obtained. Compared to DAmB, LAmB gave 186 
similar drug peak levels around 60 ng/g, but at earlier time points (after 30 minutes versus 2-187 
6 hours) and only half the total exposure. The rump-to-back AUC0.5-48h ratios (1.3 for DAmB, 188 
1.5 for LAmB) indicate that there are limited differences in skin drug exposure based on 189 
anatomical location in uninfected mice. In contrast, in L. major-infected animals, the 190 
presence of the localized cutaneous lesion on the rump (figure 1d) strongly enhanced drug 191 
accumulation for both formulations in comparison to the CL-uninfected back skin of the 192 
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same mice (figure 1f). Based on the rump-to-back AUC0.5-48h ratios, AmB levels are 6-fold 193 
higher for LAmB and 8-fold higher for DAmB. Compared to DAmB, LAmB had a similar 194 
peak concentration in skin (132 ± 28 versus 159 ± 8 µg/g) at later time points (24 h versus 6 195 
h), showing a trend of slower drug accumulation into and elimination from the lesion. AmB 196 
levels in the rump and back tissue for both formulations in infected mice was around 5-fold 197 
higher than in uninfected mice. Changes in AmB plasma concentrations after 1 mg/kg LAmB 198 
or DAmB infusion are not reflective for those in skin tissues. No adverse effects at this dose 199 
level were observed for either formulation. 200 
 201 
 202 
 203 
 204 
 205 
 206 
 207 
 208 
 209 
 210 
Multiple dose skin PK and PD in L. major-infected mice  211 
Skin distribution after multiple dosing of either LAmB or DAmB (1 mg/kg on day 0, 2, 4, 6 212 
and 8) in CL-infected mice is shown in figure 2. On day 10, intralesional levels for LAmB 213 
(542 ± 46 ng/g) were 3-fold higher than for DAmB (170 ± 18 ng/g, p<0.0001). Comparing 214 
these concentrations 48 hours after the last dosing to those found during earlier single dose 215 
PK studies at the same time point (see figure 1c and 1d – LamB: 110 ± 17 ng/g; DAmB: 92 ± 216 
4 ng/g), a gradual and linear drug accumulation in the target tissue during treatment can be 217 
assumed for LAmB but not for DAmB. Again, AmB levels in the lesion were significantly 218 
higher compared to those in the healthy back skin for LAmB (x 20, p<0.0001) and DAmB (x 219 
12, p<0.0001).  220 
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We then compared the resulting efficacy outcomes for LAmB and DAmB after complete 5 x 221 
1 mg/kg treatment. A small reduction in day 10 lesion size compared to the untreated (5% 222 
dextrose) group (9.9 ± 0.8 mm) was found for LAmB (9.4 ± 0.2 mm) and DAmB (8.7 ± 0.6), 223 
but in both cases the difference was not significant (p=0.83 and 0.34, respectively). A lower 224 
relative parasite load was also found for LAmB (2.0 ± 0.6 x 10
7
 parasites/g) and DAmB (6.1 225 
± 3.4 x 10
7 
parasites/g), but again without a statistically significant difference compared to 226 
the control (1.6 ± 0.5 x 10
8
 parasites/g, p=0.12 and 0.23 respectively). As expected, both 227 
formulations show some antileishmanial efficacy at 5 x 1 mg/kg, but the toxicity limit of 228 
DAmB (1 mg/kg) does not allow a meaningful comparison at clinically relevant dose levels. 229 
Because of this, we only further investigated the dose-concentration-response relationship at 230 
higher doses for LAmB.  231 
   232 
Dose-concentration-response of LAmB in L. major-infected mice 233 
After L. major-infected mice received 5 doses of LAmB at either 0, 6.25, 12.5 or 25 mg/kg 234 
LAmB (on days 0, 2, 4, 6 and 8), the dose level was related to the resulting day 10 235 
intralesional AmB concentrations (figure 3a) as well as response indicated by lesion size and 236 
parasite load (figure 3b and 3c respectively). Figure 3d shows the non-linear fit sigmoidal 237 
dose-response curve plotting the logarithm of these intralesional AmB levels versus relative 238 
reductions in parasite load and lesion size compared to the untreated controls (0 mg/kg). The 239 
calculated dose required to achieve 50% (ED50) and 90% of maximum effect (ED90) was 9.16 240 
and 16.73 mg/kg for lesion size. For parasite load, ED50 was 7.55 and ED90 was 9.16 mg/kg.  241 
We observed a linear dose-concentration-response relationship up to 12.5 mg/kg. Between 242 
the 0 and 12.5 mg/kg range, correlation was strong between dose-concentration (linear 243 
regression goodness of fit R
2
=0.99) and concentration-response (R
2
=0.99 and 0.91 for 244 
relative reduction in parasite load and lesion size, respectively). Little additional efficacy was 245 
found by doubling the dose from 12.5 to 25 mg/kg, while intralesional AmB levels increased 246 
nonlinearly by 5-fold; this resulted in only a small additional reduction in lesion size and 247 
parasite load. This indicates that at 25 mg/kg, the near-maximum efficacy of LAmB for this 248 
specific treatment regimen had been reached. Significant reductions in parasite load and 249 
lesion size (P<0.05) were found between the control and treated groups at all three dose 250 
levels. Doubling of the LAmB dose from 6.25 to 12.5 to 25 mg/kg range resulted in a further 251 
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decrease in parasite load and lesion size, but the differences among the groups were not 252 
significant (p>0.05).  253 
DISCUSSION 254 
 255 
The pharmacokinetics and pharmacodynamics of many drugs currently used in the treatment 256 
of CL, including different formulations of AmB, are poorly understood (15). We have 257 
investigated the single- and multiple-dose skin distribution of AmB following dosing with 258 
either the unilamellar liposome AmBisome® (LAmB) or the micellar deoxycholate salt form 259 
Fungizone® (DAmB). Significant differences in pharmacokinetics were observed between L. 260 
major-infected and uninfected animals, as well as between the two drug formulations.  261 
 262 
 263 
We observed an important impact of the CL infection on skin accumulation for both LAmB 264 
and DAmB. Drug levels in the localized lesion were over 5-to-20 fold elevated compared to 265 
those in the healthy skin tissue of the same infected mice, as well as in uninfected animals. 266 
The pathological condition of CL-infected skin, mainly caused by the severe localized 267 
inflammatory immune response against the Leishmania parasites multiplying within dermal 268 
macrophages, may explain this phenomenon. After intravenous administration, DAmB 269 
dissociates from the colloidal micelles and over 95% of AmB binds to plasma proteins (16) to 270 
from a high molecular weight association. LAmB also interacts with proteins and while 90% 271 
of AmB remains stably intercalated in the 60-80 nm sized liposomes (4, 16), coating by 272 
opsonins makes the liposomes prone to ingestion by phagocytes in systemic circulation and 273 
the reticuloendothelial system in liver and spleen (17). While these complexes have impaired 274 
extravasation in healthy skin (continuous endothelium with small vessel pores of a 6-12 nm 275 
diameter (18)), the leaky vasculature at the infection site (increased permeability, disease-276 
inflicted capillary damage) could enhance local drug accumulation (19). Another factor, 277 
especially for LAmB, is the migration of phagocytic monocytes, which can serve as potential 278 
drug reservoirs, from the bloodstream to the infection site. This is a characteristic of the 279 
early-stage and acute immune response against Leishmania (20, 21), causing small, non-280 
ulcerated CL nodules (as observed in our L. major-infected mice 12-days post-inoculation). 281 
Little is known about the elimination of AmB from the target site by local metabolism or 282 
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lymphatic drainage. However, the latter has been hypothesized as a reason behind the much 283 
lower activity of liposomal formulations of AmB (12) and sodium stibogluconate (22) when 284 
injected intralesionally compared to intravenously. The impact of these individual 285 
physiological processes on local drug distribution in skin is difficult to estimate using the 286 
current methodology, which is based on total drug levels and unable to distinguish between 287 
intra- or extracellular, as well as free, protein–bound or liposome-encapsulated AmB. 288 
Furthermore, the general limitations of tissue homogenates apply, such as loss of spatial drug 289 
disposition within the compartments of the organ of interest. Novel techniques, such as 290 
microdialysis and MALDI MS imaging, have untapped potential in pharmacological CL 291 
research to respectively measure unbound concentrations in the dermal interstitial fluid (23)  292 
or study drug disposition within the cellular architecture of infected skin (24). These findings 293 
about AmB accumulation in diseased tissue could also be relevant in the treatment of deep 294 
cutaneous mycoses (such as invasive candidiasis), where the pathogen, like Leishmania, is 295 
located in the dermis (25), instead of the superficial portions of the epidermis where most 296 
fungi typically reside.   297 
Comparing the pharmacokinetics of the individual two AmB formulations, we saw significant 298 
differences between LAmB and DAmB, consistent with previous studies (14, 26-28). Plasma 299 
concentrations and exposure were much higher for LAmB over DAmB and not reflective of 300 
changes in skin tissue levels for either formulation. Drug concentrations at the target site 301 
were similar after single intravenous dosing of the individual AmB formulations, but 3-fold 302 
higher for LAmB than for DAmB following 5-time administration of the same dose. 303 
Recently, Imam and colleagues (28) also investigated the distribution of LAmB and DAmB 304 
in L. major-infected BALB/c mice, but skin was not evaluated in this study. Increased 305 
accumulation of liposomes in inflammatory over healthy sites has also been described for 306 
subcutaneous tumours (29), bacterial skin abscesses (30, 31) and fungal infections (32). The 307 
so-called ‘enhanced permeation and retention effect’, increased drug accumulation at sites of 308 
leaky vasculature and defective lymphatic drainage, has been coined as the rationale behind 309 
nanoparticle-based drug delivery in cancer and inflammation (19). The data and our 310 
understanding of CL histopathology suggest that this effect can also be exploited as a passive 311 
targeting strategy in this context, by encapsulation of antileishmanial drugs in small (< 100 312 
nm), stable (tightly packed phospholipids with cholesterol), unilamellar liposomes (17) 313 
similar to AmBisome®. Indeed, several promising results have already been achieved with 314 
nanoparticles of AmB and other drugs for the treatment of CL (28, 33-38).  315 
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Finally, we evaluated how drug concentrations at the infection site after LAmB treatment 316 
relate to outcomes. After administration of five consecutive doses, the 1 mg/kg dose of 317 
LAmB (as well as DAmB, for which this is the tolerated maximum) proved to be too low to 318 
be therapeutic, but a linear dose-concentration-response effect was found for 6.25 and 12.5 319 
mg/kg. The clear correlation between intralesional drug levels and treatment outcomes can be 320 
explained by the known concentration-dependent manner in which AmB exerts its 321 
antimicrobial activity (39). Interestingly, for doubling the LAmB dose from 12.5 to 25 322 
mg/kg, intralesional AmB levels increased by over 5-fold. This could be due to the known 323 
phenomenon of saturation of AmB uptake and clearance mechanisms in the organs of the 324 
reticuloendothelial system, possibly resulting in higher plasma exposure and increased 325 
distribution to other tissues (40). However, little additional efficacy for 25 compared to 12.5 326 
mg/kg was observed. Both these doses were able to achieve a near-100 % reduction in 327 
parasite load but not lesion size, indicating the need for longer treatment as the host’s 328 
response to parasite elimination in the skin appears to be delayed. Results are in line with 329 
published data (12, 41) and suggest the clinical superiority of LAmB over DAmB in CL 330 
based on enhanced intralesional accumulation of the liposome, as well as already known 331 
factors such as better tolerability and potentially shorter treatment courses. Further PK PD 332 
analysis of LAmB is required to inform optimized clinical dose regimens, especially for the 333 
different complex forms of CL, as there are known differences in species-specific drug 334 
sensitivity (42), histopathology (20) and immunology (21). It is currently unknown to what 335 
degree our observations about skin accumulation of LAmB in the L. major-BALB/c model 336 
are translatable to human CL, but understanding of preclinical PK and PK PD relationships 337 
should improve the use and development of antileishmanial drugs.   338 
In summary, intravenous LAmB has potent and dose-dependent in vivo activity against CL 339 
due to relatively high drug accumulation within the lesion, which is enhanced by the inflamed 340 
state of the infected target tissue and the pharmacokinetic properties of the liposomal 341 
formulation.      342 
FIGURE LEGENDS 343 
 344 
Figure 1: Single dose pharmacokinetics of Fungizone® (DAmB, ●) and AmBisome® 345 
(LAmB, ○). Uninfected and L. major-infected BALB/c mice received one intravenous dose 346 
(1 mg/kg of body weight) of a formulation, after which amphotericin B (AmB) levels in 347 
plasma (a, b) and skin at multiple time points were determined. Two skin sites per animal 348 
were included: the rump (parasite inoculation site where the localized CL lesion is present in 349 
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infected (d), but not in uninfected (c) mice) and the back (lesion-free control site in both 350 
infected (f) and uninfected (e) animals). Each point represents the mean ± SEM (n=4-5 per 351 
group).  352 
Figure 2: Multiple dose skin pharmacokinetics of Fungizone® (DAmB) and AmBisome® 353 
(LAmB). L. major-infected BALB/c mice received intravenous doses of 1 mg/kg of body 354 
weight on days 0, 2, 4, 6 and 8. On day 10 (48 hours after the last dosing), skin samples were 355 
collected for amphotericin B (AmB) analysis. The CL lesion was localized on the rump, 356 
while the back skin served as a lesion-free, healthy control site. Each point represents the 357 
mean ± SEM (n=4-5 per group). Differences were analysed using 1-way ANOVA followed 358 
by Turkey’s multiple comparison tests and considered significant if p<0.05 (*) or not 359 
significant (ns) if not (p<0.0001: ****).   360 
Figure 3: Dose-concentration-response relationship of AmBisome® (LAmB) in experimental 361 
CL. L. major-infected mice received five doses of either 5% dextrose (0 mg/kg, untreated 362 
control), 6.25, 12.5 and 25 mg/kg LAmB (IV). On day 10, resulting intralesional amphotrcin 363 
B levels (3a), lesion size (3b) and parasite load (3c) were evaluated. Outcomes are linked in a 364 
logarithmic-scale dose-response curve plotting drug concentrations against relative reduction 365 
in lesion size and parasite load (3d, non-linear fit with variable slope). Each point represents 366 
the mean ± SEM (n=4-5 per group). Differences among day 10 outcomes were analysed 367 
using 1-way ANOVA followed by Turkey’s multiple comparison tests and considered 368 
significant if p<0.05 (*), p<0.01 (**), p<0.001 (***) and p<0.0001 (****) or not significant 369 
(ns) if not.   370 
 371 
 372 
 373 
 374 
 375 
 376 
 377 
 378 
 379 
 380 
 381 
 382 
TABLES  383 
 384 
TABLE 1 Pharmacokinetic profile of Fungizone® and AmBisome® in uninfected and L. 385 
major-infected mice after a single intravenous 1 mg/kg dose. Values for pharmacokinetic 386 
parameters are calculated from the plasma PK profiles seen in figure 1 (a, b).   387 
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 Fungizone® (DAmB) AmBisome® (LAmB) 
PK parameter Unit Uninfected Infected Uninfected Infected 
Cmax ug/ml 1.1 1.0 11.1 8.2 
AUC h · ug/ml 21.5 30.2 62.7 71.0 
Cl ml/h/kg 29.6 18.9 14.2 13.5 
T1/2 h 36.1 39.7 10.7 8.5 
Vd ml/kg 1458 1075 225 143 
 388 
 389 
 390 
TABLE 2 Skin distribution of Fungizone® and AmBisome® in uninfected and L. major-391 
infected mice after a single intravenous 1 mg/kg dose. AUC0.5-48h values are calculated from 392 
skin profiles seen in figure 1 (c, d, e, f). 393 
Skin site Fungizone® (DAmB) AmBisome® (LAmB) 
Uninfected  Infected  Uninfected  Infected  
Rump (lesion site) 1586 ± 495 6035 ± 273 863 ± 365 5270 ± 1003 
Back (control site) 1269 ± 190 710 ± 194 573 ± 142 915 ± 312 
Rump-to-back ratio 1.3 8.5 1.5 5.8 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
 402 
 403 
 404 
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